A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia

Inclusion Criteria: * 1\. Male or female patients aged ≥18 years. * 2\. Must meet the diagnostic criteria for Waldenström's Macroglobulinemia (WM). * 3\. Patients must be treatment-naïve or not have received standard prior therapy, as defined by the following conditions: a) No prior combined chemotherapy with regimens such as BR, RCD, BCD, CHOP, or COP. b) No prior therapy with fludarabine-containing regimens. c) Treatment with chlorambucil or cyclophosphamide (alone or in combination with glucocorticoids) for less than 4 weeks. d) Failure to achieve a minimal response (MR) from the above treatments. e) If any of the above treatments were previously administered, a washout period of at least 2 weeks must be completed before study treatment initiation. * 4\. Presence of indications for WM treatment, meeting at least one of the following criteria: a) Symptomatic hyperviscosity. b) Symptomatic peripheral neuropathy. c) Amyloidosis. d) Cold agglutinin disease; cryoglobulinemia. e) Disease-related cytopenia (Hemoglobin \<100 g/L or Platelet count \<100×10\^9/L). f) Massive lymphadenopathy. g) Presence of constitutional symptoms: persistent/recurrent fever (\>38°C) for over 2 weeks unrelated to infection, drenching night sweats, and/or unintentional weight loss \>10% within 6 months. h) Rapid disease progression, defined as a \>50% increase in lymph node size within 2 months, and/or lymphocyte doubling time \<6 months, and/or rapid decline in hemoglobin or platelet counts not due …